The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Glycemia reduction in type 2 diabetes–microvascular and cardiovascular outcomes
Open accessAbstract
BACKGROUND: Data are lacking on the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, with respect to microvascular and cardiovascular disease outcomes in persons with type 2 diabetes. METHODS: of body-surface area, diabetic peripheral neuropathy assessed with the Michigan Neuropathy Screening Instrument, cardiovascular events (major adverse cardiovascular events [MACE], hospitalization for heart failure, or an aggregate outcome of any cardiovascular event), and death. Hazard ratios are presented with 95% confidence limits that are not adjusted for multiple comparisons. RESULTS: During a mean 5.0 years of follow-up in 5047 participants, there were no material differences among the interventions with respect to the development of hypertension or dyslipidemia or with respect to microvascular outcomes; the mean overall rate (i.e., events per 100 participant-years) of moderately increased albuminuria levels was 2.6, of severely increased albuminuria levels 1.1, of renal impairment 2.9, and of diabetic peripheral neuropathy 16.7. The treatment groups did not differ with respect to MACE (overall rate, 1.0), hospitalization for heart failure (0.4), death from cardiovascular causes (0.3), or all deaths (0.6). There were small differences with respect to rates of any cardiovascular disease, with 1.9, 1.9, 1.4, and 2.0 in the glargine, glimepiride, liraglutide, and sitagliptin groups, respectively. When one treatment was compared with the combined results of the other three treatments, the hazard ratios for any cardiovascular disease were 1.1 (95% confidence interval [CI], 0.9 to 1.3) in the glargine group, 1.1 (95% CI, 0.9 to 1.4) in the glimepiride group, 0.7 (95% CI, 0.6 to 0.9) in the liraglutide group, and 1.2 (95% CI, 1.0 to 1.5) in the sitagliptin group. CONCLUSIONS: In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups. The findings indicated possible differences among the groups in the incidence of any cardiovascular disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; GRADE ClinicalTrials.gov number, NCT01794143.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“although no significant differences were found for major adverse cardiovascular events, hospitalization for HF, or cardiovascular death (133).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [133]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hemmingsen, B., Lund, S. S., Gluud, C. N., Vaag, A. A., Almdal, T., & Wetterslev, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub4 · Cited by 287
RetractedHemmingsen, B., Lund, S. S., Gluud, C. N., Vaag, A. A., Almdal, T., & Wetterslev, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub3 · Cited by 210
RetractedEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Flagged first, then by citations
Cited by
Sorted by citations
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“More “ + “ signs indicate a greater bene fi t. 89 – 92 Since then, it has also been approved for other indications, such as chronic weight management, under the brand name Saxenda.”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Shi, Q., Nong, K., Vandvik, P. O., Guyatt, G. H., Schnell, O., Rydén, L., Marx, N., Brosius, F. C., Mustafa, R. A., Agarwal, A., et al. (2023) · BMJ · doi:10.1136/bmj-2022-074068 · Cited by 293
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes
The GRADE Study Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200433 · Cited by 222
Self-citationLean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Kelly, T., Irvine, K., Peters, C., Zhyzhneuskaya, S., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00385-6 · Cited by 186
The impact of population ageing on the burden of chronic kidney disease
Chesnaye, N. C., Ortíz, A., Zoccali, C., Stel, V. S., & Jager, K. J. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00863-9 · Cited by 194
Xie, Y., Bowe, B., Xian, H., Loux, T., McGill, J. B., & Al-Aly, Z. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00171-7 · Cited by 104
Goldney, J., Sargeant, J. A., & Davies, M. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05988-3 · Cited by 100
Kutz, A., Kim, D. H., Wexler, D. J., Liu, J., Schneeweiß, S., Glynn, R. J., & Patorno, E. (2023) · Diabetes Care · doi:10.2337/dc23-0671 · Cited by 82
Drake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 69
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 101
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Chen, J., Yin, D., & Dou, K. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01875-8 · Cited by 67
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
Ferreira, J. P., Sharma, A., Butler, J., Packer, M., Zannad, F. M., Vasques‐Nóvoa, F., Leite-Moreira, A. F., & Neves, J. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad398 · Cited by 61
Dhanapalaratnam, R., Issar, T., Lee, A. T. K., Poynten, A. M., Milner, K., Kwai, N. C. G., & Krishnan, A. V. (2024) · Diabetologia · doi:10.1007/s00125-023-06072-6 · Cited by 50
Krishnan, A., Schneider, C. V., Hadi, Y. B., Mukherjee, D., Alshehri, B. Y., & Alqahtani, S. A. (2023) · Diabetologia · doi:10.1007/s00125-023-06057-5 · Cited by 52
Bidulka, P., Lugo-Palacios, D. G., Carroll, O., O’Neill, S., Adler, A., Basu, A., Silverwood, R. J., Bartlett, J. W., Nitsch, D., Charlton, P., et al. (2024) · BMJ · doi:10.1136/bmj-2023-077097 · Cited by 52
Selenium, diabetes, and their intricate sex-specific relationship
Demircan, K., Chillon, T. S., Bang, J., Gladyshev, V. N., & Schomburg, L. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.03.004 · Cited by 45
Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.1487 · Cited by 39
Diabetes: a review of its pathophysiology, and advanced methods of mitigation
Gupta, S., Sharma, N., Arora, S., & Verma, S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2333440 · Cited by 40
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
McCoy, R. G., Herrin, J., Swarna, K. S., Deng, Y., Kent, D. M., Ross, J. S., Umpierrez, G. E., Galindo, R. J., Crown, W. H., Borah, B. J., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00453-9 · Cited by 30
Nephroprotective Properties of Antidiabetic Drugs
Gerdes, C., Muller, N., Wolf, G., & Busch, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103377 · Cited by 30
Green, J. B., Everett, B. M., Ghosh, A., Younes, N., Krause-Steinrauf, H. J., Barzilay, J. I., Desouza, C. V., Inzucchi, S. E., Pokharel, Y., Schade, D. S., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066604 · Cited by 28
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 29
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention
Ostrominski, J. W., CHENG, A. Y. Y., Nelson, A. J., Neuen, B. L., Sattar, N. A., Tuttle, K. R., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01384-4 · Cited by 31
Lin, X., He, S., Shan, S., Xu, F., Wu, F., Li, F., Zheng, M.-H., Lei, L.-M., Duan, J.-Y., Wu, Y.-Y., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02440-7 · Cited by 28
Diabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management
Chen, D., Sindone, A. P., Huang, M., Peter, K., & Jenkins, A. J. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.06.013 · Cited by 25
Richardson, T. L., Halvorson, A. E., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Grijalva, C. G., Elasy, T. A., & Roumie, C. L. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2751 · Cited by 22
Sun, L., Yuan, Y., Li, Y., & Rao, X. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11948 · Cited by 20
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 20
New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · Biomedicines · doi:10.3390/biomedicines11041159 · Cited by 22
Kermansaravi, M., Chiappetta, S., Kassir, R., Bosco, A., Giudicelli, X., Laïnas, P., & Safieddine, M. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07564-z · Cited by 22
Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review
Epelde, F. (2024) · Medicina · doi:10.3390/medicina60121986 · Cited by 18
Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes
Vashisht, R., Patel, A. R., Dahm, L., Han, C., Medders, K. E., Mowers, R. M., Byington, C. L., Koliwad, S. K., & Butte, A. J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36613 · Cited by 21
Wretlind, A., Curovic, V. R., de Zawadzki, A., Suvitaival, T., Xu, J., Zobel, E. H., von Scholten, B. J., Ripa, R. S., Kjær, A., Hansen, T. W., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01922-z · Cited by 16
Sohn, M., Frías, J. P., & Lim, S. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15251 · Cited by 16
Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
MacIsaac, R. J., Deed, G., dʼEmden, M. C., Ekinci, E. I., HOCKING, S. L., Sumithran, P., & Rasalam, R. R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01475-5 · Cited by 17
Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 25
Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes
Neugebauer, R. S., An, J., Dombrowski, S. K., Oshiro, C. E. S., Cassidy‐Bushrow, A. E., Gilliam, L. K., Simonson, G. D., Karter, A. J., Bergenstal, R. M., Finertie, H., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.36100 · Cited by 13
Shared decision making, diagnostic evaluation, and pharmacotherapy in type 2 diabetes
Brockamp, C., Landgraf, R., Müller, U., Müller‐Wieland, D., Petrak, F., & Uebel, T. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0219 · Cited by 15
Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes
Andraos, J., Smith, S. R., Tran, A., & Pham, D. Q. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01406-6 · Cited by 18
Rahman, A., Alqaisi, S., Saith, S. E., Al-Zakhari, R., & Levy, R. (2023) · Cardiology Research · doi:10.14740/cr1523 · Cited by 13
Garvey, W. T., Cohen, R. M., Butera, N. M., Kazemi, E. J., Younes, N., Rosin, S. P., Suratt, C. E., Ahmann, A., Hollander, P. A., Krakoff, J. A., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1782 · Cited by 14
SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes
Liakos, A., Karagiannis, T., Avgerinos, I., & Bekiari, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-025-01616-z · Cited by 16
Rhee, J. J., Han, J., Montez‐Rath, M. E., & Chertow, G. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15427 · Cited by 15
Nooh, F., Ali, M. I., Chernet, A., Probst-Hensch, N. M., & Utzinger, J. (2023) · Diseases · doi:10.3390/diseases11020062 · Cited by 12
Alqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 9
Das, A., Saboo, B., Chawla, R., Aravind, S., Rajput, R., Singh, A., Mukherjee, J., Jhingan, A., Shah, P., Deshmukh, V., et al. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01192-6 · Cited by 11
Looker, H. C., Chang, D. C., Baier, L. J., Hanson, R. L., & Nelson, R. G. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104176 · Cited by 9
Schwartz, S. S., Corkey, B. E., Gavin, J. R., DeFronzo, R. A., & Herman, M. E. (2024) · BMC Medicine · doi:10.1186/s12916-024-03518-5 · Cited by 8
Kristensen, F., Christensen, D. H., Callaghan, B. C., Nielsen, J. S., Andersen, H., Sørensen, H. T., & Thomsen, R. W. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-01262 · Cited by 9
After Metformin — Next Steps for Type 2 Diabetes with Low Cardiovascular Risk
Rydén, L., & Standl, E. (2022) · New England Journal of Medicine · doi:10.1056/nejme2210531 · Cited by 8
Triglyceride glucose index as a biomarker for heart failure risk in H-type hypertension patients
Xu, Z., Yan, X., Li, D., & Huang, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-89211-w · Cited by 7
Trends in Use of Sulfonylurea Types Among US Adults with Diabetes: NHANES 1999–2020
Shin, J., Echouffo-Tcheugui, J. B., Fang, M., Grams, M. E., & Selvin, E. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08067-w · Cited by 6
Neves, J. S., Lobato, C. B., Leite, A. R., Vale, C., Vasques‐Nóvoa, F., Saraiva, F. A., Leite-Moreira, A. F., Holst, J. J., & Ferreira, J. P. (2025) · Obesity Reviews · doi:10.1111/obr.70043 · Cited by 6
Zhang, L., Liu, H., Yang, F., Zhang, Z., Wu, Y., Li, F., Dang, S., Zhang, Z., Qian, L., & Wang, R. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03492-5 · Cited by 6
Kirkman, M. S., Tripputi, M., Krause-Steinrauf, H. J., Bebu, I., AbouAssi, H., Burch, H. B., Duran-Valdez, E., Florez, H. J., Garvey, W. T., Hsia, D. S., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1332 · Cited by 6
Duodenal mucosa resurfacing: the endoscopic silver bullet against metabolic disorders?
Lonardo, A., & Singal, A. K. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.130 · Cited by 6
Gabriel, R., Boukichou-Abdelkader, N., Gilis‐Januszewska, A., Makrilakis, K., Gómez‐Huelgas, R., Kamenov, Z. A., Paulweber, B., Satman, İ., Djordjević, P., Alkandari, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12052035 · Cited by 6
Cherrington, A., Tripputi, M., Younes, N., Herman, W. H., Katona, A. M., Groessl, E. J., Craig, J., Gonzalez, J. S., Garg, R., Casula, S., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1648 · Cited by 6
Her, A., Choi, B. G., Rha, S., Kim, Y. H., & Jeong, M. H. (2024) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-23-349 · Cited by 6
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 5
Liu, W., Gu, W., Chen, J., Wang, R., Shen, Y., Lu, Z., & Zhang, L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf138 · Cited by 5
The Main Diseases Related to Type 2 Diabetes Mellitus: A Scoping Review
Silva, J. V. F. D., Borges, W. R., & Ferracioli, P. R. B. (2024) · Scientia. Technology, science and society. · doi:10.59324/stss.2024.1(2).02 · Cited by 6
Mamoun, L., Rosenbloom, A., Gasbeck, T., Ziegler, M. E., & Widgerow, A. D. (2025) · Wound Repair and Regeneration · doi:10.1111/wrr.70090 · Cited by 5
Seegmiller, J. C., Schmit, D. J., Arends, V. L., Steffes, M. W., Kahn, S. E., & Younes, N. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15072 · Cited by 5
Cherrington, A., Krause-Steinrauf, H. J., Aroda, V. R., Buse, J. B., Fattaleh, B., Fortmann, S. P., Hall, S., Hox, S. H., Kühn, A., Killean, T., et al. (2023) · Clinical Trials · doi:10.1177/17407745231175919 · Cited by 5
Banerji, M. A., Buse, J. B., Younes, N., Krause-Steinrauf, H. J., Ghazi, A., Lee, M., Park, J., Pop‐Busui, R., Underkofler, C., Fortmann, S. P., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1356 · Cited by 5
Schwartz, S. S., & Herman, M. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1394805 · Cited by 6
Effektive antidiabetische Therapie zur Vorbeugung einer diabetischen Nephropathie
Muller, N., Busch, M., Gerdes, C., & Wolf, G. (2023) · Nephrologie aktuell · doi:10.1055/a-2055-3322 · Cited by 5
New Application of an Old Drug: Anti-Diabetic Properties of Phloroglucinol
Drygalski, K., Maciejczyk, M., Krasowska, U., Ustymowicz, A., Godzień, J., Buczyńska, A., Chomentowski, A., Walczak, I., Pietrowska, K., Siemińska, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910291 · Cited by 4
Wexler, D. J., Garvey, W. T., Ghosh, A., Kazemi, E. J., Krause-Steinrauf, H. J., Ahmann, A., Brown-Friday, J., Casula, S., Cherrington, A., Elasy, T. A., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2825 · Cited by 7
Deng, Y., Polley, E. C., Herrin, J. S., SWARNA, K. S., Kent, D. M., Ross, J. S., Maron, B. A., Mickelson, M. M., & McCoy, R. G. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040217 · Cited by 3
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Lin, Y., Yi, C., Cao, P., Lin, J., Chen, W., Mao, H., Yang, X. F., & Guo, Q. (2025) · Hypertension Research · doi:10.1038/s41440-025-02142-x · Cited by 3
Siriyotha, S., Lukkunaprasit, T., Angkananard, T., Looareesuwan, P., McKay, G. J., Attia, J., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1094221 · Cited by 3
Hsia, D. S., Younes, N., Krause-Steinrauf, H. J., & Kassem, L. S. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108692 · Cited by 3
Price, J. E., Fujihara, K., Kodama, S., Yamazaki, K., Maegawa, H., Yamazaki, T., & Sone, H. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103168 · Cited by 3
Kanumilli, N., Butler, J., Makrilakis, K., Rydén, L., Vallis, M., Wanner, C., Zieroth, S. R., Alhussein, A., & CHENG, A. Y. Y. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01418-0 · Cited by 3
Sant’Anna, V. A. R., Izar, M. C. D. O., Gidlund, M., & Fonseca, H. A. R. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.07.018 · Cited by 3
Yan, J., Sun, X., Liu, X., & Li, X. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70059 · Cited by 2
Judder, M. I., Islam, M., Kaur, H., Rahman, R., Deka, K., Kapil, M. J., Pathak, B. J., Sarma, T., & Islam, M. M. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x414055250924050309 · Cited by 2
Chen, N., Cui, F., Ma, Y., Wang, J., Tang, L., Zheng, L., Xing, M., Zhao, X., & Tian, Y. (2026) · Eco-Environment & Health · doi:10.1016/j.eehl.2026.100220 · Cited by 2
Glimepiride: an old antidiabetic medication with potential as a new cardiovascular therapeutic?
Sawami, K., Tanaka, A., & Node, K. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad084 · Cited by 2
Top studies of 2022 relevant to primary care
Perry, D., Moe, S. S., Thomas, B., Lindblad, A. J., Kirkwood, J. E. M., Falk, J., Potter, J., Paige, A., & Allan, G. M. (2023) · Canadian Family Physician · doi:10.46747/cfp.6905325 · Cited by 2
The Effect of Glycemic Control on Left Ventricular Function in Clinical and Experimental Diabetes
Lavine, S. J., & Prcevski, P. (2023) · CJC Open · doi:10.1016/j.cjco.2023.06.007 · Cited by 2
Shen, J., Sarwal, A., Singh, R., Hartsell, S. E., Wei, G., Nevers, M. R., Christensen, J. C., Takyi, A., Katkam, N., Derington, C. G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16207 · Cited by 3
Carroll, O., Bidulka, P., Basu, A., Adler, A., O’Neill, S., Briggs, A. H., Lugo-Palacios, D. G., Khunti, K., & Grieve, R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16447 · Cited by 2
Xu, J., Lu, Y., Dai, C., Wu, Y., Hu, S., Yan, Z., Su, B., & Liu, Q. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.118072 · Cited by 2
Голубев, С. А. (2024) · Рецепт · doi:10.34883/pi.2024.27.1.002 · Cited by 2
Roles of Empagliflozin in Diabetic Cardiomyopathy: A Review
Luo, H., Zhang, N., Liu, Y., Chen, P., Duan, P., Lou, X., Yu, H., Lei, Q., Zhao, G., Wang, M., et al. (2025) · Current Vascular Pharmacology · doi:10.2174/0115701611319744250116092707 · Cited by 1
Pop‐Busui, R., Rosin, S. P., Butera, N. M., Krause-Steinrauf, H. J., Assi, H. A., Garg, R., Inzucchi, S. E., Katona, A. M., McGill, J. B., Mudaliar, S. R. D., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1087 · Cited by 1
Elangovan, S., Ramalingam, P. S., Sowmya, K. S., & Arumugam, S. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-06569-2 · Cited by 2
Standl, E., Ceriello, A., McGuire, D. K., Schnell, O., & Holman, R. R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02959-3 · Cited by 1
Metadata
- Authors
- The GRADE Study Research Group
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- The GRADE Study Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-09-22
- Volume
- 387
- Issue
- 12
- Pages
- 1075-1088
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9832916
- OpenAlex
- W4296702407
- Cited by
- 159
- References
- 25
- Citations by year
- 2026: 22 · 2025: 39 · 2024: 42 · 2023: 51 · 2022: 5
- FWCI
- 25.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute
- Centers for Disease Control and Prevention
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK098246, U34DK088043)
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, glycemic control, glucose-lowering medications, metformin, glargine, glimepiride, liraglutide, sitagliptin, microvascular complications, diabetic peripheral neuropathy, albuminuria, renal dysfunction, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, comparative effectiveness
- MeSH terms
- Sitagliptin Phosphate, Insulin Glargine, Liraglutide, Albuminuria, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Drug Therapy, Combination, Glomerular Filtration Rate, Heart Failure, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Metformin, Sulfonylurea Compounds, Diabetes Complications, Dyslipidemias, Microvessels, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
